Carbapenem-Resistant Enterobacteriaceae (CRE) among Children with Cancer: Predictors of Mortality and Treatment Outcome
Antibiotics · 17.02.2023 · 12 (2) · 405
DOI: 10.3390/antibiotics12020405 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 17.02.2023. Verfasst von Youssef Madney und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology, National Cancer Institute, Cairo University, Cairo 12613, Egypt. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Carbapenem-resistant Enterobacteriaceae (CRE) is an important emerging threat among pediatric cancer patients, with a high mortality rate. This retrospective study included all pediatric cancer patients with (CRE) bloodstream infections (BSIs) at a children’s cancer hospital in Egypt (2013–2017). Two hundred and fifty-four pediatric cancer patients with CRE BSI were identified; 74% had hematological malignancies, and 26% had solid tumors. Acute myeloid leukemia was the most common hematological malignancy (50%). The main clinical features for acquiring CRE-BSI were previous antibiotics exposure (90%), profound neutropenia (84%), prolonged steroid use (45%), previous colonization with a resistant pathogen (35%), ICU admission within 90 days (28%), and central venous catheter use (24%). E. coli was the most common isolated pathogen (56%), followed by Klebsiella pneumoniae (37%). All isolates were resistant to carbapenem with an MIC < 4–8 μg/mL in 100 (45%) and >8 μg/mL in 153 (55%). The overall mortality rate was 57%, and 30 day mortality was reported in 30%. Upon multivariate analysis, for the patients with Klebsiella pneumoniae BSI, carbapenem resistance with an MIC > 8 μg/mL and associated typhlitis or pneumonia were predictors of poor outcome. In conclusion, CRE-BSI is a major threat among pediatric cancer patients in limited resource countries with limited options for treatment. Antimicrobial stewardship for early detection through routine screening, adequate empirical treatment, and timely adequate therapy may impact the outcome for such high-risk patient groups.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric Oncology, National Cancer Institute, Cairo University, Cairo 12613, Egypt.
- Department of Pediatric Oncology, Children's Cancer Hospital Egypt, Cairo 57357, Egypt.
- Department of Paediatrics, Faculty Of Medicine, Benha University, Benha 15881, Egypt.
- Department of Clinical Pharmacy, Children's Cancer Hospital Egypt, Cairo 57357, Egypt.
- Department of Clinical Research, Children's Cancer Hospital Egypt, Cairo 57357, Egypt.
- Department of Clinical Microbiology, Faculty Of Medicine, Cairo University and Children's Cancer Hospital Egypt, Cairo 57357, Egypt.
ORCID-Profile: Youssef Madney, Reham Khedr, Naglaa Ahmed
Zitieren
APA
Madney, Y., Aboubakr, S., Khedr, R., Hafez, H., Ahmed, N., Elsheshtawy, K., Elanany, M., Salahelden, A., Shalaby, L., & Galal Behairy, O. (2023). Carbapenem-Resistant Enterobacteriaceae (CRE) among Children with Cancer: Predictors of Mortality and Treatment Outcome. Antibiotics, 12(2), 405. https://doi.org/10.3390/antibiotics12020405
Vancouver
Madney Y, Aboubakr S, Khedr R, Hafez H, Ahmed N, Elsheshtawy K, et al. Carbapenem-Resistant Enterobacteriaceae (CRE) among Children with Cancer: Predictors of Mortality and Treatment Outcome. Antibiotics. 2023;12(2):405. doi:10.3390/antibiotics12020405
BibTeX
@article{Madney2023,
author = {Madney, Youssef and Aboubakr, Shaimaa and Khedr, Reham and Hafez, Hanafy and Ahmed, Naglaa and Elsheshtawy, Khaled and Elanany, Mervat and Salahelden, Abdelhamid and Shalaby, Lobna and Galal Behairy, Ola},
title = {Carbapenem-Resistant Enterobacteriaceae (CRE) among Children with Cancer: Predictors of Mortality and Treatment Outcome},
journal = {Antibiotics},
year = {2023},
volume = {12},
number = {2},
pages = {405},
doi = {10.3390/antibiotics12020405}
}
EUVIMED